Latest Hotspot

Coherus announces FDA approval for UDENYCA ONBODY™, a cutting-edge pegfilgrastim-cbqv delivery technology

2 January 2024
3 min read

Coherus BioSciences, Inc., which operates as a commercial biopharmaceutical enterprise emphasizing the innovation, production, and marketing of new immunotherapy treatments for cancer, has reported that the U.S. Food and Drug Administration has given the nod to its UDENYCA ONBODY™ device. This device is an on-body injector format of the company’s product, UDENYCA® (pegfilgrastim-cbqv), a biosimilar to pegfilgrastim. It is intended for use subsequent to chemotherapy sessions to reduce the likelihood of infections indicated by the occurrence of febrile neutropenia.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

"The newly launched UDENYCA ONBODY injector is the culmination of extensive investment in R&D to create a distinctive, cutting-edge device that offers patients an automated way to administer their prescriptions," stated Denny Lanfear, CEO at Coherus. "Patients dealing with cancer, alongside their healthcare providers, can now select the most suitable form of UDENYCA delivery, whether it be a preloaded syringe, our auto-injector, or the novel on-body injector."

Paul Reider, the Chief Commercial Officer at Coherus, explained, "Our market analysis identified a substantial market need for an innovative on-body pegfilgrastim administration system that caters to the varied requirements of patients. We anticipate that the UDENYCA ONBODY's quick five-minute dispensing period and its state-of-the-art, retracting needle feature will receive positive feedback from those undergoing cancer treatment, their caretakers, and healthcare professionals."

Rich Hameister, the Chief Technical Officer at Coherus, highlighted, "Our advanced UDENYCA ONBODY injector stands out as it was specially engineered for its intended medical application, rather than being a modified version of an existing product. It represents a fresh, holistic, and original design strategy for pegfilgrastim delivery that integrates exclusive technology and user-centric design insights to ensure dependability and ease of use for the patient."

The UDENYCA ONBODY has been thoughtfully crafted with the end-user's comfort and safety as a priority. It is equipped with features such as visual indicators, acoustic confirmation signals that reassure the user of successful administration, and a robust adhesive that is generally well-accepted by the skin. Upon completion of the injection, the needle retracts on its own, minimizing the chance of accidental needlesticks.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of December 30, 2023, there are 182 investigational drugs for the CSF-3R target, including 73 indications, 204 R&D institutions involved, with related clinical trials reaching 1519, and as many as 1349 patents.

Pegfilgrastim-CBQV is a biosimilar drug developed by Coherus BioSciences, Inc. It has been approved for the treatment of hematopoietic subsyndrome of acute radiation syndrome and chemotherapy-induced myelosuppression. The drug targets the CSF-3Rreceptor and works by stimulating the production of white blood cells in the bone marrow. Its first approval occurred in September 2018 in multiple European countries, indicating its safety and efficacy in these regions.

图形用户界面, 文本, 应用程序

描述已自动生成

What are the types of protein sulfation and their implications in protein-protein interactions?
"What" Series
2 min read
What are the types of protein sulfation and their implications in protein-protein interactions?
2 January 2024
Protein sulfation is a post-translational modification, where a sulfate group gets added to a specific amino acid residue in a protein.
Read →
Research findings on Chugai's innovative multispecific antibody DONQ52, aimed at treating Celiac Disease
Latest Hotspot
3 min read
Research findings on Chugai's innovative multispecific antibody DONQ52, aimed at treating Celiac Disease
2 January 2024
Chugai Pharma announced preclinical results for their antibody, DONQ52, published in Nature Communications.
Read →
What types of drugs can apply for Fast Track Designation?
"What" Series
2 min read
What types of drugs can apply for Fast Track Designation?
2 January 2024
Fast track designation (FTD) is a process used by the U.S. Food and Drug Administration (FDA) tofacilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
Read →
LegChem Bio has entered into a licensing deal for their Trop2-focused antibody-drug conjugate known as LCB84
Latest Hotspot
3 min read
LegChem Bio has entered into a licensing deal for their Trop2-focused antibody-drug conjugate known as LCB84
2 January 2024
LegoChem Biosciences announced a licensing deal with Janssen Biotech to develop and market LCB84, a Trop2-targeted antibody-drug conjugate.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.